Podcasts about revolutionise

In this episode, we explore findings from a groundbreaking study recently published in Nature which revealed potential targets for bowel cancer prevention and treatment. The study provides the most detailed understanding yet of bowel cancer's genetic makeup. The research, which used data from the 100,000 Genomes Project identified over 250 genes that play a crucial role in the condition, driver genes and potential drug targets. Our guests discuss the potential impact of these findings on patient outcomes, screening for bowel cancer, and future prevention strategies. Helen White, Participant Panel Vice-Chair for Cancer at Genomics England is joined by Professor Ian Tomlinson, Professor of Cancer Genetics at the University of Oxford, Claire Coughlan, Clinical Lead for Bowel Cancer UK and consultant nurse in colorectal cancer, and Dr David Church, a clinical scientist fellow and a medical doctor specialising in oncology at Oxford University. "The people that were kind enough to donate samples to the 100,000 Genomes Project, they did so knowing that they almost certainly wouldn't benefit personally from their donation from their gift and that any benefits would be some way down the line and hopefully benefit others which is what we're seeking to realise now. But, you know, it's not a given when we treat people in the clinic so we're very, very grateful to those individuals." You can read more about the study in our colorectal cancer blog and our study findings news story. You can download the transcript or read it below. Helen: Welcome to Behind the Genes. Ian: One of the great hopes is that some of these new genes that we've found could be useful in preventing cancer and it doesn't necessarily matter that they're rare, even if they're only 1% of cancers, by using those and changing those in the normal individual before they have had cancer then we may be able to reduce that risk. So, there are lots of potential new targets for prevention that are coming through.  My name is Helen White and I'm the Participant Panel Vice-Chair for Cancer at Genomics England. Today I'm delighted to be joined by Professor Ian Tomlinson, Professor of Cancer Genetics at the University of Oxford, Claire Coughlan, Clinical Lead for Bowel Cancer UK and consultant nurse in colorectal cancer, and Dr David Church, a clinical scientist fellow and a medical doctor specialising in oncology at Oxford University.   Today we will be discussing a pioneering colorectal cancer study which using data from the 100,000 Genomes Project has uncovered new insights that could transform diagnosis and treatment for patients with bowel cancer. If you enjoyed today's episode we would love your support, please like, share and rate us on wherever you listen to your podcast.  Thank you for joining me today. We're going to be discussing the findings from a landmark study that has been published in nature. This study used data generously donated by people with bowel cancer who took part in the 100,000 Genomes Project giving us the most detailed look yet at the genetic makeup of colorectal cancer better known as bowel cancer. But before we get into that let's start by hearing from my guests. Could each of you please introduce yourselves.  Ian: I'm Ian Tomlinson, I work at the University of Oxford and most of my work is research into bowel cancer, it's genetic causes, the genes that are involved in actually causing the cancer to grow which may be different from genetic causes and also the use of that data to help patients whether guiding future treatments or potentially helping to prevent bowel cancer which would obviously be our optimum strategy to have the biggest impact on the disease and its incidents.   Claire: So, I'm Claire Coughlan, I'm the clinical lead for Bowel Cancer UK and my remit at the charity is to ensure that everything we do is clinically relevant and that we're providing services that meet the needs of those affected by bowel cancer and the educational needs of those health professionals that work with people affected by bowel cancer. I'm also a nurse consultant in colorectal cancer at Lewisham and Greenwich NHS Trust and I lead an urgent referral service there and also work with patients with late effects of bowel cancer.  David: I'm David Church, I'm a medical oncologist and Cancer Research UK advanced clinician scientist at the University of Oxford. I treat bowel cancer clinically and do research on bowel cancer and womb cancer including a lot of research using samples and data from Genomics England data service we're discussing today of course.  Helen: Great, thank you. Now let's turn to Claire to learn more about bowel cancer. Claire, can you share with us how common it is, how treatable it is and if there are any trends in terms of which groups of people are affected?  Claire: Of course, bowel cancer is a relatively common cancer, there are about 46,000 people each year in the UK diagnosed with bowel cancer so that is quite a large number. The thing that really drives us forward in bowel cancer is that the earlier stage you're diagnosed at the greater chance of survival. So, the figures for that are quite stark, we stage bowel cancer through stage one to 4 with one being the earliest stage and 4 being the most advanced.   If you are diagnosed with bowel cancer at stage one you have a 9 in 10 chance of being alive and well 5 years after your diagnosis of bowel cancer. And if you're diagnosed at the other end of the spectrum at stage 4 that drops to a 1 in 10 and should people survive after a diagnosis of stage 4, which more people than before do they will have had a lot of treatment for their bowel cancer so the burden of the treatment will also be with them after that. So, it's really important that we diagnose at the earliest possible stage which is why studies such as the one we're going to talk about today are so important.   We have noticed that there has been a slight increase in being diagnosed at a younger age. That said the latest statistic is 2,600 people were diagnosed under the age 50 in the UK last year so it's still a disease of older people, you still have a greater chance of getting bowel cancer as you get older but it's really, really important that we're aware that you can still get bowel cancer as a younger person.   Probably one of the most exciting things that has happened for bowel cancer of recent years is our bowel cancer screening programme and the age for that now has been brought down to 50, we're not quite there all over the country, but in the UK that is the aim that everyone will be screened for bowel cancer at the age of 50. So, yes it's a common disease and staging an early detection is vital. Helen: That's lovely Claire, thank you very much for that. David, turning to you could you please explain to us how bowel cancer typically develops? David: Yes, so we know compared with many cancer types quite a lot about how bowel cancer develops because the bowel is accessible to collect samples by a technique called endoscopy which is putting a camera into the bowel from which you can sample tumours or lumps. And so from genetic research done in the last 10 years we know that, or we've known for many years actually, for much longer, that cancer is a genetic disease, it's a disease caused by alterations in genes and particularly genes that control whether the cells in our bowel grow normally and die normally as they should do. And collectively when there are alterations in genes that regulate those processes you can have a cell or collection of cells which are able to grow without restraint and don't die when they should do which are some of the hallmarks of a cancer and they also require the ability to spread elsewhere in the body which is what kills people with cancer including bowel cancer. We know from research done in the last 10 to 15 years that some of the alterations in genes that can cause bowel cancer in combination occur very early in our life, even in the first and second decade of life, but don't cause cancer. The earliest detectable abnormality is typically a polyp which is a tumour, a lump within the bowel which is detectable and if removed is almost certainly cured by removal alone but if it's not detected then as that grows and acquires more alterations in genes then it can become a cancer and cancers develop the ability to invade the bowel wall, to spread to what we call lymph nodes or glands nearby and also to spread further afield, most commonly to the liver or to the lungs.   And for most people whom bowel cancer has spread to the liver or to the lungs or elsewhere unfortunately we're not able to cure their disease which as Claire has said is why there is such an importance in detecting cancers and pre-cancers as we call them so that the tumours are not actually cancerous but come before bowel cancer as early as possible.  Helen: Thank you David. Moving on to the study, Ian perhaps you can take this, in the study that you carried out my understanding is that the whole genome sequencing was used to investigate the genetic changes that lead to the development and growth of bowel cancer. And for this participants with bowel cancer in the 100,000 Genomes Project donated both a blood sample and a tumour sample while those with rare conditions only provided a blood sample, can you explain why that is?  Ian: As you said the study really looked at 2 quite separate arms albeit with a little bit of overlap as we'll see. So, one very important aim was to look at individuals, both children and adults, who had medical problems or other conditions that were unexplained but which had some features that suggested that they weren't necessarily inherited but there may be some variation in their genes that had caused them, and roughly half of the programme was dedicated to that.   Within that there was a small number of people who had a strong family history of bowel cancer or who had large numbers of polyps in the bowel and they were analysed in a separate part of the project from what we're mostly discussing. Within the cancer arm there was a collection really throughout England of patients who had most of the common types of cancer and a few with less common cancers.   And because when we're looking at genetic and related changes in cancers we need to make sure that those changes have actually occurred in the cancer as it started growing from its earliest stages with a small number of cells in the body that were slightly abnormal and then progressing. We need to look at what genetic variation the patient has in all the cells of their body. We don't want to look at patients and say that looks an interesting change, we may be able to use that if it's present in all of the normal cells in that patient's system.   We want to make sure the change is specific to the cancer itself and therefore we have to sequence both a sample probably taken from blood and a sample taken from the actual cancer. And in a way we subtract out the changes in the blood to identify the changes that have actually occurred in the cancer itself.  Helen: That's a very helpful explanation. Does this research show that there is a role for whole genome sequencing in clinical care?  Ian: I think my own view is it is all a question of cost. I think the advantages it provides it can assess multiple types of genetic change at once. It is relatively consistent across each cancer's genome between cancers, even between centres mean that it is the method of choice. There are undoubtedly developments that will happen in the future, maybe being able to sequence longer stretches of DNA in one go that will help the analysis.   And some of the computational methods are likely to develop to identify some of the slightly difficult to identify genetic changes but it ought to be the standard of choice. There are issues and potential difficulties in collecting the high-quality samples that have been needed from pathology laboratory and that will be difficult going forward with current budges and there are lots of challenges but ultimately it in some form has to be the method of choice. What wasn't done is to look at other molecule tests or essays, looking at RNA wasn't really done on a big scale as well as DNA and other changes to DNA apart from the genetic changes were not looked at.   So, there are certainly ways it could be improved if you had limitless money but I think the project, 100,000 Genomes has shown the whole genomes are. They have a lot of advantages and ultimately probably will be adopted by the NHS and similar organisations.  Helen: David, could you now tell us about the findings of this pioneering study and what impact these findings might have on people with bowel cancer in the future?  David: So, this is the largest study to date to analyse the entire genome of bowel cancer by some margin and the fact that we've done whole genome sequencing and in so many people it has really given us an unprecedented ability to identify the genetic alterations that drive bowel cancer. And within bowel cancer we've known for some time it is not a homogeneous entity that bowel cancer is not all created equal, that there are sub-groups of bowel cancer and we have been able to refine those over previous efforts. And I guess if you were to ask what the biggest take home for me from the study is it's just the complexity of the disease.   So, as we've mentioned we know that cancer is a genetic disease, that it's driven by genetic alterations, alterations in genes which regulate the growth of cells or the death of cells or the spread of cells. And we've known for many years that there is a modest number of genes which are commonly malfunctioning in bowel cancer and they would be in the tens to dozens really. But with this work we've hugely extended our understanding of the genes that drive bowel cancer and in fact we've discovered nearly 250 genes which are altered in bowel cancer and appear to drive the growth of the cancer.   Now we know that not all of those will be validated and by that I mean that there are associations that we find at the moment, not all of which will be biologically relevant but interpreted in the data we know a large number that are previously undiscovered are or we can be fairly confident of that. And one of the take homes from that is that many of these are only altered in a small fraction of bowel cancers.   So, rather than being perhaps half of bowel cancers or a third of bowel cancers there are a good number of genes, a very substantial number of genes, which are altered in say 3 to even 1% of bowel cancers. And if we think about how we go about targeting those and perhaps we'll come onto treatment later that poses really challenges for how we work and we would think about treating patients with bowel cancer who have those particular alterations in their cancers.  Helen: Thank you David, yes we'll come onto treatment shortly, but I think Claire has a question for you.   Claire: Yes, thank you. For me as somebody who works in this every day this is such an exciting and interesting study, particularly in light of what we said earlier about early detection and how critically important that is for improving outcomes in people with bowel cancer. So, in your view do you think this research could help shape future screening programmes or prevention strategies?  David: That's a great question, I suppose in terms of screening at the moment the majority of screening is done in the UK at least by testing for blood in the stool which is relatively non-specific so I'm not sure that that would be directly impacted by this research. But one area of early cancer detection that is perhaps more relevant is quite a lot of work including from Oxford actually in recent years looking at blood tests. So, testing blood samples for early detection of cancer whereby you can test for genetic alterations, fragments of DNA that have alterations from the bowel cancer or any cancer that circulates in the blood and that tends to rely on a small number of common alterations.   And with this data I could see that we might be able to refine those tests and in so doing improve our early detection of cancer but that would need quite some work before we could actually say look that had real potential I think. And in terms of prevention there are, I think Ian may want to come in on this, one or 2 sub-groups which you might think that you could try to prevent but of course that needs a lot of extra work really.   But I think we have some clues of the biology of bowel cancer and particularly some of the sub-groups where you might think well this drug would work better in terms of preventing that sub-group or that sub-group but that will need to be the subject of future study.  Helen: Ian, did you want to come in on that at all?  Ian: So, at the moment prevention is a fairly new way of helping to reduce the number of people with bowel cancer at the level of the whole population which is what we have in the UK above a certain age group as we heard from Claire earlier. The methods used, again as we heard, are screening for occult blood in the stool and then colonoscopy to identify either hopefully early cancers or polyps and remove those. But when we think about the methods that we use for preventing other diseases then normally where they're successful using a more easily delivered and I have to say less expensive method.   So, high blood pressure is treated to reduce the risk of cardiovascular disease and there are other diseases where those what you might call molecularly-based prevented strategies are coming in. We really lack that for bowel cancer in particular, it does happen for some other cancers, but one of the great hopes is that some of these new genes that we've found could be useful in preventing cancer. And it doesn't necessarily matter that they're rare, even if there are only 1% of cancers, by using those and changing those in a normal individual before they have had cancer then we may be able to reduce that risk.   So, there are lots of potential new targets for prevention that are coming through and as David said it is going to take a lot of work to work out which of those are deliverable and who will benefit. But we have quite a lot of opportunities in that space and although that may not be us that takes that forward, it may be, but it may not be. We think it is a lot of material for those interested in chemo prevention using drugs of cancer that they can work on and with luck deliver some new ways of preventing cancer that may be simply popping a pill every morning to take your risk right down to as close as zero as we can.  Helen: Thank you Ian. David, I think you had something to add here.  David: Thanks Helen. One area of prevention that we're really interested in Oxford and many others are is using the genetic alterations that we find in bowel cancers and other cancers as targets for vaccination. Now we know that gene alterations will cause abnormal proteins which while they might drive the cancer, make it grow or not die, can also be recognised by the immune system so the abnormal proteins can be recognised by the immune system as being foreign and as foreign they can be targeted by the immune system so the immune system will try and kill the cells carrying those alterations. And we know for some sub-sets of bowel cancers those alterations can be relatively predictable actually, they occur in quite a sizeable fraction of some sub-groups of bowel cancers.   And one area that we're particularly interested in at the moment and actively pursuing is using those targets where you need some additional work to demonstrate when they are particularly recognisable by the immune system. But to use these genetic alterations is potential targets for vaccination with the intention ultimately of preventing bowel cancer in at risk individuals or ideally in the full-term time the whole population. And we've received some funding from Cancer Research UK to pursue this line of research and we have a group working on this in Oxford and as I say many others do elsewhere.  Helen: Thank you David, yes I have a vested interest in this because my understanding is this work is aimed primarily at people with a genetic condition called lynch syndrome which predisposes the people who have inherited this gene change alteration to bowel cancer, womb cancer and other cancer. And I had womb cancer, as I think David you know, a few years back and discovered it was due to lynch syndrome and so it's really exciting that you're now looking at vaccinating preventing because yes I take aspirin every day, I have my colonoscopy every 2 years which have some effect on preventing these cancers but it's not 100% guaranteed. And I don't suppose it ever will be but having the vaccination in that armoury would be fantastic I think for future generations, it's very exciting and we look forward to hearing more about it.   Thank you Ian and David. I mean we've heard a lot there about preventing bowel cancer but I think moving back now to potential treatments, you know, we've heard from David how this study has shown a number of actionable findings but what are the next steps towards treatment? How can these findings be turned into real actions that will benefit those people diagnosed with bowel cancer in the future? Ian, perhaps you would like to pick up on this to start.  Ian: That step is one, you know, in which I'm not personally an expert but a lot of the newer treatments are based on the finding of so called driving mutations which are simply genetic changes that occur as the cancer grows and contribute to that growth and ultimately if it's not treated to the spread and dissemination of a cancer. And the fact that we have reported 250 which need validation but of which a large proportion are likely to be true drivers means that anyone of those can be a potential new target.   The criteria to be used for which of those mutations to pursue, which of those driver genes to chase up are quite complicated normally, depend on many things such as the interest of research groups and small and larger drug companies. And the similarity of those genes to other genes that have evolved and the processes that they make to go slightly wrong in the cancer.   So, there is also the issue that because these are uncommon, everybody talks a lot about personalised medicine or precision medicine, this would be truly precision or personalised medicine because a genetic change that was driving the cancer in only 1% of patients is obviously not a huge number of patients although bowel cancer is a common cancer so it's not a tiny number either. But it would mean investment at that level to benefit let's say 1 to 2% potentially of all patients with bowel cancer but I think that's a nettle we have to grasp. And I think our results are showing that most of the really common drug changes either have not yet been successfully targeted in treatment or are too difficult to target.   So, we're going to have to start looking at these less common genetic drivers and design strategies, inhibitors, you know, again that can be delivered to patients relatively straightforwardly in order to see whether they benefit the patients concerned. But there is this problem of getting enough patients enrolled in clinical trials where a change is only present in a relatively small proportion of all the patients with that cancer type.   Helen: Thank you Ian. Presumably if there is a relatively small number of patients the people who are looking at running these trials might be looking at perhaps international trials, would that be one way to go?  Ian: So, I think David can speak with more personal knowledge but there are international trial networks and there are collaborations along these lines already under way. I would hope that those could be made use of even more than they are already. There is, you know, a financial consideration for those developing new anticancer treatments which are, you know, high risk work and also the costs of setting up trials and enrolling people is not a trivial thing. So, I think those are hurdles that can be overcome but it would need a concerted effort to do that. Patients will play a major role in that and patient organisations as well as 100,00 Genomes and other similar projects.  Helen: Yes, thank you, David I don't know if you want to come in on that.  David: Yes, the challenge of testing therapies in small groups is a very real one and there is lots of interest at the moment in exploring alternatives to conventional clinical trials. And as we use more electronic patient records and we have pharmacy records so there is the potential to get those data from routine clinical practice and there is lots of investments and attention on that at the moment so called real world data which is always an interesting term as if patients in clinical trials aren't in the real world which of course they are.   But it's perhaps a little more cost effective sometimes in clinical trials, of course it does pose its own challenges in how you disentangle true treatment effect from other factors because there are many factors impacting on how long people with cancer live. But there is a lot of investment and effort going into that at the moment and it will be interesting to see how that develops over the coming years.  Helen: Turning to you Claire based on your experience how well do you think people with bowel cancer understand how genomes can help with their care and what support is currently available to them in this area?  Claire: I think the answer, as it is so often is, it's dependent on individuals and not just one individual. So, I think some patients are very motivated to know as much about this as possible and to understand and to know what the next steps may be in their own treatment that may be helped by this. Others don't want to have the same knowledge and want to be guided very much by their medical teams but I think oncologists obviously are at the forefront of this and we see at the charity … we have services at the charity that supports patients and we see lots of queries into our ask the nurse service where people have been given variable information about I suppose personalised medicine as Ian alluded to and how their very specific bowel cancer may be treated, so I think it varies from patient to patient.   There is support available so we have the ask the nurse service I alluded to. We have a brilliant patient forum actually and everybody in clinical practice will have seen this, patients often become more expert than anybody and they share advice and they're moderated forums that are a very safe place for people to ask questions where there is a moderator to ensure that it is made really clear that circumstances are individual.   And the same with the ask the nurse service because you don't have all the clinical information so it is about empowering people, so there is support available. I think the other thing that is really important is equipping specialist nurses with the knowledge that they need to support their patients. This is a really exciting area of evolution for bowel cancer particularly I think in all cancers at the moment but for bowel cancer I think things have changed fairly rapidly in recent years and specialist nurses really need support in knowing that they have up-to-date information to give their patients.   So, that's another challenge for us and any specialist nurses that might be listening to this podcast we have online education on genomics for specialist nurses. Just while we're talking about that and you mentioned lynch syndrome earlier, so there has been a lynch syndrome project as I'm sure you're aware where we're trying to get testing for lynch syndrome brought into local hospitals.   So, there was some funding via NHS England so that the testing be done at time of diagnosis, so a pre-test and then a final test if that's appropriate, for everybody diagnosed with bowel cancer to see if they have lynch syndrome. And in some trusts that has been done and in others it hasn't yet and the funding hasn't quite followed in the way that we need it to enable that to happen. It's vitally important, we think there are about 175,000 people in the UK with lynch syndrome and we only know about 5% of them. And this is a gene change that is an inherited gene change so we can do what we call cascade testing where we test family members and we can then employ preventative strategies to prevent people from developing bowel cancer.   So, it's a really important project, so I think as well as supporting patients with the information around the changes that are happening in this area we also need to ensure that we support the workforce and have investment there to enable the support of all the changes and the genomic landscape.  Helen: Absolutely Claire and so much resonates there with what you've said. Having myself had cancer discovered that was due to lynch syndrome, cascade testing offered to my family members so valuable. It turns out I inherited my change from my mum who is 83, has never had cancer, so I think that's a very good example of, you know, it doesn't necessarily mean that you will get cancer but actually on that point that you made about empowering patients I always have a right smile because there is my mum going off to all her other medical appointments because at 83 she sees quite a few people and she is always the one telling them about lynch syndrome and educating them because most of them haven't heard of it, so yes it's really, really important.   And that patient forum, you're probably aware of Lynch Syndrome UK, I don't have any involvement in that other than being a member but that is so valuable for people with a particular condition to go somewhere where they can talk to or listen to other people with a similar condition, really, really valuable.   Right, well I think circling back really to the 100,000 Genomes Project I think you touched on this earlier David but reflecting on what you and Ian have told us about your study what is it about the 100,000 Genomes Project bowel cancer dataset that made this work possible?  David: There are a few things, one of which and not least of which is the sheer size of the effort. So, to have whole genome sequencing for more than 2,000 individuals is previously unprecedented and we'll be seeing more of this now as we scale up our research efforts but at the inception of the project it was very, very ambitious and to be able to deliver that is a huge achievement. And the quality and breadth of the analysis is very strong as well.   And ultimately, you know, the former gives thanks to the people that were kind enough to donate samples to the 100,000 Genomes Project, they did so knowing that they almost certainly wouldn't benefit personally from their donation from their gift and that any benefits would be some way down the line and hopefully benefit others which is what we're seeking to realise now. But, you know, it's not a given when we treat people in the clinic so we're very, very grateful to those individuals.   And I think also to the scientists who worked incredibly hard over the last 5 years to deliver this work actually. So, having been part of the team and being lucky enough to be part of the team along with Ian we've had hugely motivated individuals that really have dedicated a large fraction of their working lives to delivering this project which I think is a fantastic achievement as well.  Helen: Thank you, thank you to all those participants who at a time when their lives probably were turned completely upside down by a cancer diagnosis were offered the chance to join the 100,000 Genomes Project and said yes. As you say most of them will have known that it won't have helped them but by donating their data, you know, it has allowed this work to happen and potentially it could change lots of people's lives in the future, so thank you to them.  Ian: Could I also just emphasise and agree with what David has said, I won't go through all the individuals by name, but if anybody wants to read the published report of the work there are several people on there, Alex Cornish is the first author, but many colleagues from an institute of Cancer Research, The University of Manchester, Birmingham, Leeds, other universities in London that all contributed, but also colleagues in the NHS and/or universities who recruited patients, collected samples, processed them etc and of course the people who did the preparation of the samples in genetics laboratories and actually did the sequencing and basic analysis too.   So, it is a truly huge effort across particularly all the cancer types which is particularly a complex collection given the fact the tumour is needed and a blood sample. It's quite difficult in a way to find a formal way of thanking them for all of this but without them it wouldn't have happened.  Helen: On that note I think we'll wrap up there. A huge thank you to our guests, Professor Ian Tomlinson, Clare Coughlan and Dr David Church for an enlightening discussion on the groundbreaking study published in nature. This research is set to reshape our understanding of colorectal cancer and pave the way for new possibilities in treatment and patient care.   If you would like to hear more like this please subscribe to Behind the Genes on your favourite podcast app. Thank you for listening. I have been your host, Helen White. This podcast was edited by Bill Griffin at Ventoux Digital and produced by Naimah Callachand. 

Send us a textIn this episode, Darren chats with Michael Adamson, CEO - South Africa at eShandi. The world of lending is undergoing a seismic shift, with innovators like Ishandi redefining what it means to deliver financial services in Africa. Mike shares the journey of this rebranded challenger bank and its mission to address unmet needs in the lending ecosystem across Africa.Highlights:

This week we spoke with Guy Elliott, Executive Vice President, Industry Lead TMT Global, Retail and Consumer Products EMEA and APAC for Publicis Sapient. We discussed how AI can help retailers optimise their supply chains to be more resilient and efficient and how it will change retail business models in the future.

In this special ADSTAR series of the Defence Connect Spotlight podcast, Liam Garman sits down with Andrew Seedhouse, chief of space, intelligence, national security and cyber division at Defence Science and Technology Group (DSTG), and Andre Luiten, co-founder and managing director of QuantX Labs, to examine the world of quantum technology. Throughout the podcast, the trio discuss how quantum technology works, before explaining how it can be used to revolutionise the future battlefield from radio frequency (RF) sensing to precision navigation and timing (PNT). They then discuss how Australian researchers have become world leaders in this field and how we can expand the quantum industry. Enjoy the podcast, The Defence Connect team

Send us a textIn this episode, Darren chats with Idan Jaan, Co-Founder & COO at Flexclub. Idan tells us about the many challenges the automotive industry is facing and how FlexClub is transforming vehicle access in South Africa.Highlights:

Let's be honest - amidst the deadlines, commitments, and responsibilities, it's your health that often takes a backseat. But pause for a moment and consider this: your health is your most valuable asset, and it's worth protecting at all costs.Seriously, without your health, what do you have?No amount of wealth, success, or material possessions can replace the vitality and well-being that comes from being in good health. Your health is the foundation upon which everything else in your life is built. It's the key that unlocks the door to a life of joy, fulfilment, and limitless possibilities.So, how do you protect this precious asset?After receiving a diagnosis of osteopenia, I found myself on a journey to prioritize self-care and well-being, especially as I navigate the hormonal changes of perimenopause and menopause. Join me in this episode of the Ageless and Awesome podcast as I share how proactive steps like proper nutrition and maintaining healthy habits can be transformative. Together, we'll explore how self-care not only helps regulate the nervous system but also ensures a fulfilling and active future. With personal insights and practical tips, you'll discover the importance of taking charge of your health and happiness amidst life's many responsibilities.Send me a text! Want my FREE Radiant Reset Hormone Detox for Perimenopausal Women? Of course you do! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Click here and download now.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Are you a woman feeling stressed, flat and experiencing the challenges of perimenopause? It's time to reclaim your youthful energy, radiance and self-assurance (and your ideal weight). I'm here to help with my proven method. Here's how I can support you - 1. Hit your health and wellbeing goals this year, balance your hormones and lose weight with your own personalised protocol, based on your body's biochemistry. Sounds awesome right!! Book a free 30 minute Introduction Call with me so we can discuss your health and wellbeing goals and also see how I might be able to support you. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Book your call here. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 2. The 10 Day Radiant Reset Hormone Detox for Perimenopausal Women has been designed to give you the tools to nourish and detox your body at a cellular level while supporting your hormone balance and your gut health so that you feel revitalised and in control without feeling deprived. Click here to learn more. 3. Follow me on Instagram and Facebook - ...

In this episode of the Digital Disruption Podcast, hosts Pete Gatenby and Chris Williams delve into the role of standardised, shareable data in transforming the home buying and selling process. The discussion focuses on how the adoption of "Horizontal Digital Integration" (HDI) and data standards can significantly streamline transactions, reduce redundancy, and improve customer experiences in the UK property market. Key points include: The Digital Disruption Newsletter: This monthly publication provides insights on digital transformation in home buying and selling. Importance of Data Standards: Implementing reusable data standards can eliminate repetitive tasks, like multiple ID checks, accelerating transaction times and enhancing efficiency. Benefits to Stakeholders: Lenders, brokers, and other actors stand to gain from increased predictability and interoperability. For example, lenders can better predict closing dates, enhancing customer experience and opening new revenue opportunities. Practical Steps for Industry Actors: The episode encourages stakeholders to map their data processes, collaborate within the ecosystem, and invest in technology upgrades to remain competitive. Listeners are also invited to join the live recording event on December 5th 2024, celebrating the 50th episode of the podcast. For more insights, visit our website or connect with us on LinkedIn. To connect with Pete on LinkedIn visit - Pete's LinkedIn profile To connect with Chris on LinkedIn visit - Chris's LinkedIn profile For more insights and assistance in your digital transformation, visit https://www.novus-strategy.com/ and connect with us on LinkedIn at https://www.linkedin.com/company/novus-strategy/ or email us at hello@novus-strategy.com.  

Welcome to another episode of ScaleUp Radio! I'm your host, Granger Forson. You can learn more about my journey and mission at www.bizsmart-gloucestershire.co.uk or connect with me on LinkedIn (https://www.linkedin.com).   Today, we dive into the inspiring entrepreneurial saga of Roman Loban, the dynamic founder behind two innovative fintech companies, Xiva and FMPay. Both businesses aim to reshape how micro-businesses handle their financial transactions, with a special focus on inclusivity and local community support in Cheltenham.   In this episode, Roman shares how he bootstrapped his way to fintech innovation, starting with FMPay and later introducing Xiva, each complementing the other's services. Roman's approach to building a local yet expansive company—currently boasting about 30 staff members, with a core team in Cheltenham—illustrates his commitment to community and accessible business practices.   We'll explore the challenges he faced in recruitment, culture cultivation, and lead generation, and how these experiences shaped his business philosophy.   Roman also discusses his future plans for FMPay and Xiva, focusing on expanding services and solidifying their status as the go-to payment providers for Southwest England. He shares valuable lessons on the importance of balancing technological advancement with human interaction, ensuring that every client feels connected and supported.   Roman's journey is not just about building successful businesses but also about empowering others, fostering a sense of ownership among his team, and maintaining a deep commitment to his vision despite the hurdles. This episode is a must-listen for anyone interested in the intersections of technology, entrepreneurship, and community impact.   To ensure you don't miss any inspirational future episodes do subscribe to ScaleUp Radio wherever you like to listen to your podcasts.   So, let's now dive into the inspiring journey of innovation, leadership, and community with Roman Loban.   Scaling up your business isn't easy, and can be a little daunting. Let ScaleUp Radio make it a little easier for you. With guests who have been where you are now, and can offer their thoughts and advice on several aspects of business. ScaleUp Radio is the business podcast you've been waiting for.   If you would like to be a guest on ScaleUp Radio, please click here: https://bizsmarts.co.uk/scaleupradio/kevin   You can get in touch with Granger here: grangerf@biz-smart.co.uk     Kevin's Latest Book Is Available! Drawing on BizSmart's own research and experiences of working with hundreds of owner-managers, Kevin Brent explores the key reasons why most organisations do not scale and how the challenges change as they reach different milestones on the ScaleUp Journey. He then details a practical step by step guide to successfully navigate between the milestones in the form of ESUS - a proven system for entrepreneurs to scale up. More on the Book HERE - https://www.esusgroup.co.uk/   Roman can be found here: https://fmpay.me/ https://xiva.com/ https://www.linkedin.com/in/roman-loban/   Resources: Extreme Ownership by Jocko Willink - https://uk.bookshop.org/p/books/extreme-ownership-how-u-s-navy-seals-lead-and-win-jocko-willink/651009?ean=9781250183866 Lex Fridman Podcast - https://lexfridman.com/podcast/ Chat GPT - https://chat.openai.com WhatsApp - https://web.whatsapp.com/

Siloton, a Bristol-based health technology startup, has secured £860,000 to progress the commercial rollout of its groundbreaking eye imaging chip technology, which could help address the UK's most common cause of sight loss. Siloton's technology aims to make the diagnosis and monitoring of a range of treatable retinal diseases more affordable and accessible, by compressing a tabletop-worth of heavy, expensive, and fragile components onto a single chip smaller than a £1 coin. The company says the technology could save the NHS over £1 billion annually and allow patients to monitor their condition at home, rather than having to regularly attend hospitals. RNIB Connect Radio's Toby Davey caught up with Siloton's Chief Executive Dr Alasdair Price to find out more about this ground breaking eye imaging chip technology, what form it might take and when patients will be able to start monitoring their eye conditions from home rather than having to go for regular eye Hospital Clinic Appointments.  To find out more about Siloton and their ground breaking eye image chip technology do visit their website -  https://www.siloton.com Image shows the RNIB Connect Radio logo. On a white background ‘RNIB' written in bold black capital letters and underline with a bold pink line. Underneath the line: ‘Connect Radio' is written in black in a smaller font.

In this episode, I sit down with Christina Delay, Ph.D. the visionary founder of ALTINA Drinks, a company revolutionising the non-alcoholic wine industry with a scientific approach and a deep appreciation for native Australian botanicals. With a background in Chemical Biotechnology and Plant Biology, Christina shares her personal journey of disrupting the beverage world. Motivated by the search for alcohol alternatives that retain the same complexity and enjoyment, she turned her expertise toward crafting unique, botanically infused wines. Unlike other non-alcoholic wines, ALTINA avoids sugar and grape juice concentrates, opting instead for native Australian botanicals that offer depth and character, creating a taste experience celebrated worldwide.  In this engaging conversation, we explore: Christina's vision and how she brought ALTINA from idea to fruition, building it into a major player in the non-alcoholic wine space.  The meaning behind every element of ALTINA—from branding and labelling to ingredients—making the product a journey of discovery beyond wine.  Christina's passion for mentoring startups, offering logistical and business guidance through her Canberra-based hub, fostering innovation and growth in the local entrepreneurial community.  Tune in for an inspiring discussion about disrupting industries, fostering innovation, and redefining experiences—without alcohol!  https://altinadrinks.com/

A new cost-effective, simple blood test could be the answer to accurately diagnosing and treating Alzheimer's Disease. The test is able to detect how much of the disease is in the brain, and how advanced the Alzheimer's is allowing for more targeted therapies.  Leading Alzheimer's researcher based at The Florey, Austin Health and Australian Dementia Network Professor Christopher Rowe told Milsy and Karl on 6PR Breakfast the test has the potential to revolutionise the treatment of Alzheimer's. See omnystudio.com/listener for privacy information.

Confide, your company's future compliance command centre? In this episode of Open For Business, we speak with Pav Gill, Founder and CEO of Confide—a platform designed to streamline compliance and risk management for organisations.Pav shares his remarkable journey, from exposing the €24 billion Wirecard scandal to creating a tech solution that helps companies manage sensitive reports and protect whistleblowers. We explore how his experience at Wirecard shaped Confide, the challenges of building a compliance-focused tech startup, and how the platform could redefine the future of corporate risk management by automating and simplifying compliance, governance, and whistleblowing.

Check this out: Guarantee 30 Qualified Project Quotes Over The Next 90 Days! Learn more here: https://tradie.wiki/pod Learn more about the CRM that DOES IT ALL for your trade business! Just click on this link: https://tradiehub.net Join a global community of 6000+ trade professionals https://www.facebook.com/groups/TheSiteShed Connect with me on LinkedIn. For more podcast episodes, you can also visit our website. Thank you for tuning in! If you enjoyed this podcast and this series, please take 5 to leave us a review: Google Facebook Podcast

The scale for which AI will impact the sports industry is up for debate, so StreamTime Sports co-hosts Nick Meacham and Chris Stone decided to have at it.  Key points: Does big tech actually impact sports? What are the current practical uses for AI? Is innovation coming for your job? How can AI help leaders make decisions? 

Episode 89 - The Courage to Revolutionise the TV Industry - Curtis and Cara Leopardo, started We the Studios a family-owned streaming platform dedicated to providing quality, family-friendly content. Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

Tao Climate, a leading innovator in carbon removal measurement, reporting and verification (MRV) technology, is proud to announce that it has joined the prestigious European Space Agency (ESA) Business Incubation Centre (BIC) Ireland programme. This collaboration marks a significant milestone in Tao Climate's mission to harness space technology to drive sustainability in industrial hemp cultivation. Through this programme, Tao Climate will integrate advanced satellite imaging technology developed by ESA into its MRV platform to monitor the growth of industrial hemp, a versatile crop known for its significant carbon absorption capabilities. This initiative will enable precise tracking of hemp cultivation by Tao Climate's partners, providing critical data to ensure optimal growth conditions and maximise the crop's carbon removal potential. Tao Climate is poised to address one of the most pressing challenges in the carbon removal market: verification. By leveraging ESA's satellite technology, Tao Climate aims to develop a robust system for accurately verifying carbon removal from hemp cultivation. This innovation will not only enhance transparency in the carbon market but also incentivise sustainable farming practices on a global scale. Gary Byrnes, CEO of Tao Climate, expressed his enthusiasm for the collaboration: "The intersection of space technology and sustainability is where we see the future. By leveraging the European Space Agency's satellite imaging capabilities, we can monitor hemp growth with unprecedented accuracy, solve the carbon credit verification problem, and build a foundation for a more sustainable future. This partnership is a testament to the transformative power of space tech in tackling the climate crisis." Peter Finnegan, ESA Space Solutions Ireland Manager, said: "We are delighted to welcome Tao Climate to the ESA Business Incubation Centre (BIC) Ireland network. Their innovative use of space technology to address global challenges, such as carbon removal through industrial hemp cultivation, illustrates the types of pioneering technology that we aim to support. "By integrating ESA's satellite imaging technology into their platform, Tao Climate is not only advancing the verification of carbon removal but also demonstrating the transformative impact space assets can have on sustainability efforts." ESA BIC Ireland supports Irish companies across the business spectrum that are developing technologies using space assets, resources or solutions that can be used in space. The initiative is managed by ESA Space Solutions Ireland, a Consortium Partnership made up of the following entities: Tyndall National Institute (Lead Partner), Dublin City University, Maynooth University, Technological University of the Shannon, and University College Dublin. The ESA BIC Ireland programme provides Tao Climate access to technical expertise, funding opportunities, and a network of space industry leaders, positioning the company at the forefront of the global technology movement towards a greener, more sustainable planet. See more stories here.

It's a special episode of 'Ted Talks' The Ted Hanky Podcast this week as I welcome stand up comedian turned author Micky P Kerr to the show. You may remember Micky from when he got to the final of Britain's Got Talent, Micky is a huge football fan and he has now written a book called 'Football The Peoples Shame : How to Revolutionise a National Sport' You can pre-order / purchase the book from Amazon here: https://amzn.eu/d/9KZHRSS DISCLAIMER - It's quite a serious podcast this week so don't expect the usual silliness. This show is also available for your eyes as well as your lugs ... over on the YouTube channel. Check it out here

In this episode discover what it takes to become an effective leader. Having clarity and purpose is crucial for organisational success as well as assembling diverse teams and understanding different personality types.Paul Pester is the Chair of Tandem Bank, and previously Group CEO of Virgin Money, which he led the business to become one of the first digital consumer financial services in the UK, and CEO of UK challenger bank, TSB.Music credit: David Cutter Music / @dcuttermusic Hosted on Acast. See acast.com/privacy for more information.

Episode 140 with Charles Miller, who is Director of Strategic Alliances and Development at Solynta. Charles also serves as a board member of the African Seed Trade Association and on the American Seed Trade Associations International Committee. In addition, Charles is a member of the International Seed Federations Value Chain Expert Group.Solynta uses hybrid potato breeding to grow a more sustainable future. Their mission is to create global solutions for food and nutritional insecurity by offering farmers better, stronger, and more cost-efficient ways to grow crops.What We Discuss With CharlesChallenges faced in promoting hybrid breeding as a solution for more climate-resilient crops in Africa.Given that climate change is impacting global agriculture, how will the seed industry, especially in Africa, evolve in response?How is Solynta ensuring that African farmers have access to potato varieties that can thrive in increasingly unpredictable climates?What are some of the biggest barriers African farmers face in accessing climate-resilient seeds?The major regulatory challenges encountered when scaling seed innovations across different African countries.Did you miss my previous episode where I discuss Leveraging Cloud Technologies to Accelerate AI Innovation and Economic Development in Africa? Make sure to check it out!Like this show? Please leave us a review here -- even one sentence helps!Connect with Terser on LinkedIn at Terser Adamu, and Twitter (X) @TerserAdamuConnect with Charles on LinkedIn at Charles Miller, and Twitter (X) @solyntaDo you want to do business in Africa? Explore the vast business opportunities in African markets and increase your success with ETK Group. Connect with us at www.etkgroup.co.uk or reach out via email at info@etkgroup.co.uk

Professor of Molecular Modelling at UL, Damien Thompson joins Joe to discuss the discovery his research team has made that could revolutionize computing. Hosted on Acast. See acast.com/privacy for more information.

This week, our Industry Development & Insights Director, Marie-Clare Puffett, chats with Tanguy Le Falher, Head of Retail Partnerships at Unlimitail, about revolutionising Retail Media Networks (RMNs). They explore the key drivers shaping the future of RMNs, the transformative role of technology, and how these networks will evolve beyond just in-store and online opportunities.

In this thought-provoking episode, we delve into the extraordinary moment that forever changed my perspective on focus, clarity, and precision—not only in the military  but in the chaos of everyday life.  I reflect on the struggle between panic and calm, and the lessons learned from a moment of stillness in the heat of the moment, we explore how these principles apply to modern challenges faced by entrepreneurs and business owners. Discover why the urgency to act can often lead us astray, and how finding stillness can enhance our effectiveness and decision-making. This episode reveals six proven techniques to cultivate stillness in both body and mind—essential for achieving optimal performance. Whether you're navigating the pressures of a small business or facing life's daily distractions, learn how to ground yourself and take deliberate aim at your highest values. Tune in to find out how the power of stillness can redefine your approach to success, productivity, and personal growth. Don't miss out on insights that could transform your journey—visit TomFoxley.me for additional resources! Blog Link

Many couples come to me complaining of a dissatisfying love life: some are in a low-sex or no-sex relationship, while others experience sex as boring and mechanical. In this episode, Diana Richardson shares her “Slow Sex” program, and suggests how you can create a more loving sexual partnership, well into old age.  We discuss: Tantric sex, love and sexual fulfilment. How to make sex a conscious decision, not an accidental encounter  How slowness increases sensitivity and awakens the body's innate mechanism for ecstasy  The healing spiritual power of slow sex.  Diana Richardson is considered one of today's leading authorities on human sexuality, and she is known as the pioneer of Slow Sex. She has written eight books on how a person can experience a more fulfilling sex and love life.  Born in South Africa in 1954, she first qualified as a lawyer and then trained as a massage therapist in the UK. Her interest in the body and healing prompted an intense personal exploration into the union of sex and meditation - the essence of Tantra. Since 1993, together with her partner, Michael, she has been sharing her insights and experiences with couples who travel from many different parts of the world to participate in their informative and life changing ‘Making Love' Retreats in Switzerland. Subscriber Content This Week  If you're a subscriber to The Meaningful Life (via Apple Podcasts, Spotify or Patreon), this week you'll be hearing:  How to Discuss Sex With Your Partner Three things Diana Richardson knows to be true.  AND subscribers also access all of our previous bonus content - a rich trove of insight on love, life and meaning created by Andrew and his interviewees. Follow Up Get Andrew's free guide to difficult conversations with your partner: How to Tell Your Partner Difficult Things Take a look at Andrew's new online relationship course: My Best Relationship Tools https://courses.andrewgmarshall.com/relationship-tools  Visit Diana Richardson's website. Watch Diana Richardson's TEDx talk on The Power of Mindful Sex Read Diana Richardson's books, including  Tantric Sex for Lovers  Tantric Orgasm for Women Tantric Sex for Men   Slow Sex  Join our Supporters Club to access exclusive behind-the-scenes content, fan requests and the chance to ask Andrew your own questions. Membership starts at just £4.50.  Andrew offers regular advice on love, marriage and finding meaning in your life via his social channels. Follow him on Twitter, Facebook and YouTube @andrewgmarshall 

In this enlightening episode, Paul Taylor sits down with Dr. Emily Leeming, a dietitian and gut microbiome expert with a PhD from King's College London. They dig deep into the fascinating world of gut health, exploring how what we eat shapes our internal ecosystem and influences our overall well-being. From the surprising impact of early life events on our microbiome to the power of fiber and fermented foods, this conversation covers the latest research and practical tips for nurturing your gut health. Dr. Leeming shares insights from her innovative studies on diet, gut health, and brain inflammation, shedding light on the intricate gut-brain connection. Whether you're curious about the long-term effects of C-sections, wondering why Melbourne has such high allergy rates, or just looking to improve your diet, this episode offers something for everyone interested in the hidden world inside us all.  What You'll Learn: Diving into the hidden world of your gut Your microbiome's origin story starts before birth The Impact of birthing method on a newborn's microbiome What influences microbiome development Can you renovate your gut? The truth about microbiome makeovers Gut feelings – How your belly bacteria influence your brain The unsung hero in your digestive drama Not all fiber is created equal A gut-health grocery list Whole foods vs. isolated nutrients - Which is better for gut health? Will your microbes dictate your diet? The future of personalised diets based on individual microbiomes   Key Takeaways: Your first dose of microbes comes from birth. Your immune system and your gut microbiome are very much in tandem throughout your life. A more diverse gut microbiome is effectively a healthier gut microbiome. Our gut microbiome is a living ecosystem and we are able to change it throughout our life.  Our gut microbiome is involved with our brain, and this can affect our mood, our cognition, and our behaviour as well.  Fiber is the closest thing we have to a superfood and is not just important for our gut microbiome but our whole body health. Getting enough fiber rich containing foods and fermented foods that feed our gut bacteria are key important things to have in our diet.  The BGBGs – beans, greens, berries, grains, and nuts and seeds are big high fibre hitters and are rich sources of other phytonutrients that are important for our gut and brain health.    Connect with Emily Leeming: Website: dremilyleeming.substack.com , https://www.emilyleeming.com/ LinkedIn: linkedin.com/in/dr-emily-leeming-phd-rd-615b5566 Instagram: https://www.instagram.com/dremilyleeming/    Support the Podcast:If you found this episode valuable, please consider subscribing, rating, and leaving a review on your preferred podcast platform. Your support helps us reach more people with important conversations like this one. Share this episode with someone who might benefit from hearing it—emotional eating is more common than we think, and this conversation could make a difference in someone's life.See omnystudio.com/listener for privacy information.

Andrew Dudum founded Hims & Hers to try to bring healthcare into the digital age. The business is a wellness platform that specialises in treatments for conditions that traditionally have a stigma attached, such as hair loss, acne and erectile dysfunction. It allows people access to over-the-counter drugs and prescriptions following an online consultation with a qualified doctor. The company went public on the New York Stock Exchange in 2021. It is now valued at more than $3.5bn (£2.7bn) and has more than 1.7 million subscribers. Dudum says he has built the business while aspiring to be “the least interesting person in the room”. This is the story behind how he did it... Hosted on Acast. See acast.com/privacy for more information.

A brand new week can only mean one thing... a FREASH 30 minutes of lukewarm golf banter from your favourite golfing pair, it is Golf Is Ruining My Life. This week the lads delve back into the post box to ask your most requested questions - how do I break 100, who is better a society member or regular golf club member and HOW do you get your kids into golf? - Email - thetom@golfisruiningmylife.co.uk Tik Tok - https://www.tiktok.com/@golfisruiningmylife Youtube - https://www.youtube.com/@GolfIsRuiningMyLife - New episodes every Monday & Thursday!! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Approximately 75 million people with diabetes need to inject themselves daily with insulin. Research led by Dr Nick Hunt of the University of Sydney has developed a new type of oral insulin tablet based on nanotechnology.

Host Ben Owden engages in a thought-provoking conversation with Dr. Soumya Swaminathan, a renowned pediatric leader and former WHO Chief Scientist. They explore the interconnected relationship between health and climate change and the role of transformative leadership in addressing these complex challenges.The conversation explores the need for innovative thinking, diversity of thought, and collaboration to tackle these issues. Dr. Swaminathan shares insights from her career, stressing the importance of humility, empathy, and listening to affected communities in transformative leadership. She also addresses the challenges of misinformation and the necessity of public health communication.Ben Owden speaks with Dr. Muthoni Ntonjira, Managing Director and Health Systems District Leader for Philips East Africa. They explore the transformative impact of AI on healthcare, emphasizing the need for inclusivity and equity. Dr. Ntonjira shares her journey from a medical officer to a leader in health tech, highlighting the importance of diverse data sets in AI development and the critical role of women in decision-making positions. She discusses overcoming imposter syndrome, the significance of mentorship, and the necessity of male allyship to foster a supportive environment for women in tech. Important Links*Join Thrive in the Middle Today! *Book WhyLead to Train Your Teams*Explore Our ServicesSocial Media*Ben Owden's LinkedIn*Ben Owden's Twitter 

Hundreds of military personnel from Britain, Australia and the US tested out autonomous drones and artificial intelligence in the California desert as part of an Aukus exercise. The Times' defence editor Larisa Brown explains how the sensors and algorithms could change warfare. Plus, an update on the turmoil in Bangladesh with The Times' world affairs editor Catherine Philp.The World in 10 is the Times' daily podcast dedicated to global security. Expert analysis of war, diplomatic relations and cyber security from The Times' foreign correspondents and military specialists. Watch more: www.youtube.com/@ListenToTimesRadio Read more: www.thetimes.com Hosted on Acast. See acast.com/privacy for more information.

Get Noticed! Send a text.Are you an entrepreneur struggling to scale your business efficiently? Discover how virtual assistants (VAs) can be your strategic partners, not just low-cost task handlers. Elizabeth Eiss, founder of Results Resourcing, reveals the power of hiring professional VA teams to boost your productivity and revenue. Learn why AI won't replace human VAs and how to leverage their expertise to optimise your business processes. Elizabeth shares insights on selecting the right VA, managing workflows effectively, and the true cost of DIY entrepreneurship. She introduces a fascinating ROI of Time Calculator to help you value your time and make informed decisions about outsourcing. Whether you're a solopreneur or small business owner, this episode offers valuable strategies to free up your time, focus on core activities, and accelerate business growth.Recommended book: "Thank You for Being Late: An Optimist's Guide to the Age of Acceleration" by Thomas L. FriedmanBuzzsprout - Let's get your podcast launched!Start for FREEBrilliant copy writing toolAI copywriting tool to generate unique copy, predict performance and increase conversions.Prowly - the media relations platformProwly has everything you need to get your PR work done.Build responsive quizzes.Generate higher quality, higher converting leadsDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the Show.Am I adding value to you?If so - I'd like to ask you to support the show.In return, I will continue to bring massive value with two weekly shows, up to 3 hours per month of brilliant conversations and insights.Monthly subscriptions start at $3 per month. At $1 per hour, that's much less than the minimum wage, but we'll take what we can at this stage of the business.Of course, this is still free, but as an entrepreneur, the actual test of anything is if people are willing to pay for it.If I'm adding value to you, please support me by clicking the link now. Go ahead, make my day :)Support the show here.

UC Today's Kieran Devlin speaks to Brandon Carl, EVP of Product Strategy at Smarsh, and Theo Hill, Senior Director of Product Management at Smarsh.In this session, we discuss the following:How Smarsh helps customers innovate while remaining compliant with AIWhat compliance agility means for enterprisesWhat makes Smarsh's AI capabilities stand out

As the broker channel works tirelessly to secure competitive rates for clients, innovative platforms such as Sherlok provide a wealth of opportunities. In this episode of In Focus, sponsored by Sherlok, we sit down with Adam Grocke, the platform's founder and CEO, to learn more about the platform and how technologies such as artificial intelligence (AI) and machine learning can revolutionise client retention. Tune in to find out: The opportunity for brokers to write significant volumes from existing clients. The benefits of leveraging innovations such as AI and machine learning. How Sherlok's retention and refinancing platform works. And much more!

Episode 140 of the Long Covid Podcast is a chat with Jess Dove London, CEO of the startup "Turnto". Jess tells the story behind Turnto and how it's now helping people with ME/CFS & Long Covid. We talk about the app, it's main features and how it can help.Have you enjoyed the app? Let us know! https://turnto.ai/downloadMessage the podcast! - questions will be answered on my youtube channel :) For more information about Long Covid Breathing, their courses, workshops & other shorter sessions, please check out this link(music - Brock Hewitt, Rule of Life) Support the Show.~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~The Long Covid Podcast is self-produced & self funded. If you enjoy what you hear and are able to, please Buy me a coffee or purchase a mug to help cover costs.Transcripts are available on the individual episodes hereShare the podcast, website & blog: www.LongCovidPodcast.comFacebook @LongCovidPodcastInstagram & Twitter @LongCovidPodFacebook Support GroupSubscribe to mailing listPlease get in touch with feedback and suggestions or just how you're doing - I'd love to hear from you! You can get in touch via the social media links or at LongCovidPodcast@gmail.com**Disclaimer - you should not rely on any medical information contained in this Podcast and related materials in making medical, health-related or other decisions. Ple...

Welcome to Lean Made Simple, a podcast about transforming your business — and life — one step at a time. In this episode, Ryan Tierney from Seating Matters delves into standard work and how he is in the process of revolutionising his factory by documenting every single process. Along the way, he and Producer Matt talk about:- What is standard work?- The key piece of advice given to him by world class lean leaders. - What Toyota said about the standard work in his factory. - How to take your first step in creating standards- The simple tool Ryan and his team use to create standard works. Check it out! Links: - Book a Lean Made Simple Tour: https://www.leanmadesimple.com/book-a... - Send a voice message/question to the show: https://www.speakpipe.com/LeanMadeSimple- - GEMBADOCS: https://gembadocs.com/signup

In this episode of the IEA Podcast, Tom Clougherty and Matthew Lesh are joined by Sam Dumitriu, Head of Policy at Britain Remade, to discuss Labour's ambitious plans for housing, infrastructure, and economic growth. The conversation delves into the party's strategy to reform the planning system, restore housing targets, and streamline infrastructure projects. Sam provides insights into the challenges faced by previous governments and explores whether Labour's approach can overcome the long-standing obstacles to development in the UK. The discussion covers a range of topics, including the impact of NIMBYism, the complexities of the planning process, and the potential for private sector involvement in infrastructure projects. The panel examines the role of judicial reviews in delaying major developments and debates the merits of Labour's proposed National Wealth Fund. This episode offers a comprehensive analysis of the UK's housing and infrastructure challenges, providing listeners with a deeper understanding of the issues at stake and the potential solutions on the horizon. Our goal is to bring you a public affairs podcast with a difference. We want to get beyond the headlines and the shallow political commentary you'll get elsewhere and focus instead on the big ideas and foundational principles that classical liberals should care about. Get full access to Insider at insider.iea.org.uk/subscribe

Did you know that the "inner winter" phase of our menstrual cycle, during menstruation, is a time for introspection and rest?

Willow's Witty Wisdom: Revolutionising Houseplant Care.  Cat Comforts: The PaWz Automatic Smart Litter Box Revolution.  Travel Troubles: Tech-Driven Scams Skyrocket.  Morse Mastery: Modern Magic with a Minimalist Morse Code Translator.  Neurotargeting's Nefarious Nexus: Data-Driven Democracy Dilemma.  Robotic Repetition: Humanoids Hone Skills by Shadowing Humans.  Perth Pupils' Prolonged IT Prowess: Years of Hacking Exposed.  Digital Discoveries: Delving into Genealogy with Gadgets.  Emotional Empathy: Elevating AI's Understanding. 

Repost from 2020 | What happens when a neuroscience enthusiast shifts gears to revolutionise the olive market? Meet Olly Hiscocks, the mastermind behind Olly's, a vibrant brand that's breathed fresh life into olives, nuts, and snacking pretzels. Olly's journey began with just 50 pounds and a kitchen full of experimental flavours tested on friends and family before making it big. Listen as Olly reveals the quirky character names behind his products, the importance of eye-catching branding, and how his story of persistence, passion, and authenticity led to early sales success.Ever wondered about the unexpected pitfalls in the food industry? Olly shares a surprising tale involving improperly stored garlic and an enlightening conversation with a CEO that shaped his business mindset. Explore the power of an authentic story in the entrepreneurial world as we discuss my own career shift from neuroscience to founding a startup. Together, we highlight the thrill of sales, the necessity of relentless pursuit, and how genuine narratives resonate with customers and drive impressive results.Navigating the challenges of entrepreneurship, Olly opens up about the dynamic experience of being a single founder, overproducing for Sainsbury's, and handling lockdown excess supply. Discover the importance of networking, mentorship, and community initiatives like the Nest Foundation, which empowers women to start their own businesses. Learn why delegating responsibilities and hiring skilled team members is crucial for growth, and why taking risks and experimenting with new ideas are vital steps toward long-term success. If you're passionate about the food industry or entrepreneurship, this episode is packed with invaluable insights and inspiring stories.Support the Show.

There's no such thing as totally 'straight', new study on sexuality says. NAKED FURY Female tourist sparks anger in Thailand after stripping naked and rubbing herself against sacred penis-shaped rock. Sex robots REVOLUTIONISE adult industry with cyborg babes starring in X-rated movies 

Today, we're diving into the transformative power of mindful listening, whilst it may not sound exciting - but listening is so important. It has the ability to revolutionise our relationships with ourselves and those around you.In our busy, noisy and let's face it, distracted world, truly hearing has become a rare and precious gift.Join us as we explore how giving someone your full, undivided attention can not only deepen your connections but also unlock hidden realms of understanding and empathy.Discover the magick that unfolds when you set aside your own thoughts and truly open your ears and heart to another's words.Get ready to experience the profound connection that comes from being fully present in conversation and the ripple effects it can create in your relationships and your world.-- -- -- -- -- -- -- --Deepen into Your Five-Minutes of Magick experiencewww.FiveMinutesOfMagick.com1: Get The Five-Minutes of Magick JournalA Daily Diary of Enchantment' to transform your world in just a few moments each day.Available on Amazon:Amazon UKAmazon US2: Download the A Pinch of Magick AppStep into the realm of the extraordinary with 'A Pinch of Magick', your pocket-sized portal to enchantment.Download for free at the App StoreDownload for free at the Play Store3: Join Our Magickal CommunityExplore your magick and power in a safe, fun and supportive space.Join us in our Facebook Community

Market intelligence platform, MarketSizer, has announced the closing of its pre-seed funding, totalling €1M. This round was led by venture capital firm Delta Partners with additional support from Enterprise Ireland and angel investors. The capital will be used to develop new features in the platform, accelerate additional job creation and help to support expansion into the UK and US market. Founded in 2023 by Niall O'Gorman, MarketSizer aggregates millions of data points to deliver real-time intelligence, helping businesses identify high-probability targets, optimise sales, improve marketing efforts and increase customer retention. MarketSizer is quickly positioning itself as a leader in the market intelligence space for SaaS companies, with future plans to expand into other sectors and markets. Niall O'Gorman, Founder and CEO at MarketSizer, commented: "Our pre-seed funding marks a significant milestone for MarketSizer, enabling us to expand our reach and enhance our platform. With over 25 years in the tech industry, I founded MarketSizer to address a critical gap in the SaaS sales process. Our mission is to turn vast datasets into actionable insights, helping sales teams target the right opportunities at the right time. "The sales intelligence market is projected to grow from $3.8 billion in 2023 to $9.2 billion by 2032. MarketSizer aims to capture a substantial share of this expanding market. The future of business growth lies in making swift, data-driven decisions, and MarketSizer's insights empower companies to stay ahead, adapt, and seize opportunities, defining the next generation of market intelligence." In MarketSizer, O'Gorman leverages decades of extensive experience in scaling ventures and first-hand knowledge of the challenges businesses face regarding market intelligence, having previously been one of the founders of ChannelSight. Dermot Berkery, Partner at Delta Partners, commented: "In a market where leading SaaS companies are facing growth challenges, MarketSizer's innovative approach to subscription intelligence is a standout. We believe in their vision and expertise to transform data-driven decision-making. We are excited to support their international growth and continued development." Anne Lanigan, Divisional Manager of Technology and Services at Enterprise Ireland, commented: "Pioneering Irish innovators are having a global impact as they develop world-class innovations and cutting-edge solutions, and MarketSizer is a great example. Enterprise Ireland is committed to supporting Irish companies like MarketSizer to start and scale, in order to achieve their global ambition. We are proud to support MarketSizer on this journey, including providing Pre Seed and Innovative HPSU funding. I would like to congratulate Niall and the team on this important milestone. " See more stories here.

Both developed and developing countries have experimented with social stock exchanges over the past two decades with little success. Can India's model be the gamechanger in social funding? We discuss the concept and implementation of the Indian social stock exchange with Dr. R. Balasubramian, Chair of SEBI's Social Stock Exchange Advisory Committee.

Have you ever felt that your message just isn't getting through to your clients or team members? In today's competitive agency environment, where clarity and connection can make or break relationships, mastering the art of storytelling in communication is paramount.  Whether you're struggling to convey complex ideas or seeking to build stronger, more empathetic connections with clients, honing these skills can transform your interactions. By tuning into this episode of The Agency Accelerator podcast, you'll discover how to: 1. Harness the emotional power of storytelling to create memorable and impactful communications with your team and clients. 2. Use analogies to simplify and clarify complex concepts, making them more accessible and relatable. 3. Build deeper, more empathetic client relationships, fostering trust and understanding in every conversation. Questions answered in this episode Q: Why is storytelling so powerful, particularly in a work context? Q: How can analogies simplify complex ideas and make abstract concepts more tangible? Q: What impact does storytelling have on our brain's neural pathways and our ability to retain information? Q: What are some practical tips for tailoring analogies to a specific audience or client? Q: How can you use storytelling and analogies to forge deeper connections with your team and clients? Q: Why is it important to integrate storytelling and analogies into your communication arsenal, and how can it transform your interactions? Quotations "Stories tap into our emotions in a way that dry facts and figures simply can't. They create connections that transcend mere data." – Rob Da Costa, The Agency Accelerator "Imagine buying a coffee and demanding a free croissant—that's what over-servicing your clients looks like. Analogies like these help us understand poor business practices." – Rob Da Costa, The Agency Accelerator Rate, Review, & Subscribe on Apple Podcasts “I enjoy listening to The Agency Accelerator Podcast. I always learn something from every episode.” If that sounds like you, please consider rating and reviewing my show! This helps me support more people like you to move towards a Self-Running Agency. How to leave a review on Apple Podcasts Scroll to the bottom, tap to rate with five stars, and select “Write a Review.” Then, let me know what you loved most about the episode! Also, if you haven't done so already, subscribe to the podcast. I'm adding a bunch of bonus episodes to the feed and, if you're not subscribed, there's a good chance you'll miss out. Subscribe now! Useful links mentioned in this episode: Discover more about AskRobAnything, your AI Agency CoachGet further support for your agency

Law firm Schindlers has set up a tokenised exchange for raising capital and trading real-world assets such as houses, solar power systems and real estate. Maurice Crespi, managing partner at Schindlers Attorneys, says this is a financial revolution with potentially vast implications for traditional stock exchanges. Moneyweb Crypto news articles

A new study has found machine learning can significantly improve patient outcomes in the ICU. Wellington intensive care specialist, Professor Paul Young, also Deputy Director of the Medical Research Institute explains.

"Discover the Future of Online Medical Consultations with Patchs: Unique AI, Language Translation, and Telephone Assistant!

There's no such thing as totally 'straight', new study on sexuality says. NAKED FURY Female tourist sparks anger in Thailand after stripping naked and rubbing herself against sacred penis-shaped rock. Sex robots REVOLUTIONISE adult industry with cyborg babes starring in X-rated movies Sky Pilot Radio The Soundtrack of your Life 60's thru the 80's 

Katie shares tips for overcoming the afternoon slump, by taking in the transformative power of 20 minute power naps and how they can rejuvenate your workday. Whether you're a busy professional, a creative thinker, or anyone in between, learn how a brief escape into rest can enhance focus, creativity, and overall performance. Join Katie's community and subscribe to her newsletter: https://www.katiebrindle.com Disclaimer: Yang sheng techniques are designed to support your overall wellbeing and should not be used as a substitute for any medical treatment you may be undergoing. You should not use the information in this podcast for diagnosing or treating a health problem or disease. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode Judith Germain speaks to Thomas Ryan about how AI can revolutionise sales and customer service. Key Takeaways AI can respond to sales leads and customer inquiries 24/7/365 for improved response times. AI call centers can eliminate wait times and transfer customers seamlessly without human interaction. AI can generate high volumes of written content like articles, but may lack personality or soul without proper prompting. Tools like ChatGPT, Claude, and Midjourney are extremely valuable for automating workflows. In this conversation Thomas described using AI to automatically generate hundreds of articles a month for clients, editing them to build quality content for search engine optimisation faster and cheaper than traditional agencies. Thomas shared how his daughter is using AI to illustrate her children's book, generating hundreds of images until achieving her vision of perfection by modifying prompts. Thomas advised learning AI skills now as the most valuable career path, showing how tools like ChatGPT can solve any problem by having a computer do the work of many people, saving vast time. Thomas Ryan is the Founder of Bigly Sales. You can find out more about our guest and today's episode in this Maverick Paradox Magazine article here. --- Maverick leadership is all about thinking outside the box and challenging the status quo. It's about having the courage to take risks and the confidence to lead in a way that is authentic and genuine. But amplifying your influence as a leader isn't just about having a strong vision or a big personality. It's also about having the right leadership capability and being able to execute on your ideas and plans. The consequences of not having the right level of influence as a leader can be significant. Without the ability to inspire and motivate others, you may struggle to achieve your goals and make a real impact. How Influential Are you? Take the scorecard at amplifyyourinfluence.scoreapp.com and see.  Catalysing Transformation - 1 min video Judith's book: The Maverick Paradox: The Secret Power Behind Successful Leaders.  Judith's websites:  The Maverick Paradox Magazine - themaverickparadox.com The Maverick Paradox Website - maverickparadox.co.uk Judith's LinkedIn profile is here, her Twitter profile (MaverickMastery) is here, Facebook here and Instagram here.